Myasthenia Gravis Market to Expand Significantly by 2034, States DelveInsight Report | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC

The Key Myasthenia Gravis Companies in the market include - Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others.

DelveInsight's "Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Myasthenia Gravis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myasthenia Gravis Market Forecast [https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Myasthenia Gravis Market Report:

*
Among the 7MM countries the Myasthenia Gravis market size was valued approximately USD 3,880 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In April 2025, Impressive findings from the Phase 3 clinical trial (NCT05737160) evaluating the safety and effectiveness of Telitacicept (also known as RC18; brand name: Registered ) in individuals with generalized myasthenia gravis (gMG) were presented during the Late-Breaking Science Session at the 2025 American Academy of Neurology (AAN) Annual Meeting.

*
In March 2025, Immunovant has opted not to seek regulatory approval for its myasthenia gravis (MG) therapy, batoclimab, even though the Phase III trial achieved its primary goal of reducing disease symptoms. Instead, the company plans to use the trial data to support the advancement of its alternative candidate, IMVT-1402. The Phase III randomized study (NCT05403541) evaluated the effects of weekly or bi-weekly batoclimab dosing in acetylcholine receptor antibody-positive (AChR+) patients, measuring improvements through the Myasthenia Gravis Activities of Daily Living (MG-ADL) score over 12 weeks.

*
In December 2024, Cartesian Therapeutics has shared updated efficacy and safety results from its Phase IIb trial evaluating Descartes-08, an mRNA cell therapy candidate for generalized myasthenia gravis (MG). The findings demonstrated durable responses at 12 months. This open-label, double-blind, placebo-controlled, crossover study (NCT06038474) enrolled 36 symptomatic patients who had previously undergone extensive treatment. Participants were divided evenly, with one group receiving a placebo and the other receiving Descartes-08. Both groups underwent six weekly outpatient infusions, administered without the need for prior chemotherapy-based preconditioning.

*
In October 2024, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune disorders, announced plans to present findings from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). The data will be shared at the 2024 Myasthenia Gravis Foundation of America (MGFA) Scientific Session, held during the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting.

*
The combined myasthenia gravis market size in the European Union's four largest economies and the United Kingdom was approximately USD 950 million in 2023. This figure is expected to increase over the forecast period from 2024 to 2034.

*
In June 2024, Johnson & Johnson (NYSE: JNJ) has announced encouraging outcomes from the Phase 3 Vivacity-MG3 trial of nipocalimab in patients with generalized myasthenia gravis (gMG). The trial demonstrated that patients receiving nipocalimab alongside standard of care (SOC) showed significant improvement in the MG-ADL score over 24 weeks compared to those on placebo plus SOC, meeting the primary endpoint. These findings are part of eight abstracts Johnson & Johnson will present at the 2024 European Academy of Neurology (EAN) Congress. Additionally, the data will be included in regulatory submissions later this year.

*
In January 2024, Johnson & Johnson reported the headline findings from the critical Phase III VIVACITY trial of nipocalimab in adults with generalized myasthenia gravis (gMG). In this Phase III study, nipocalimab met its primary goal, demonstrating a statistically significant decrease in MG-ADL score from baseline during weeks 22 to 24 compared to placebo (PBO).

*
According to DelveInsight's evaluation in 2023, the seven major markets (7MM) had an estimated 297,000 diagnosed prevalent instances of myasthenia gravis, with an expected upward trajectory in these cases anticipated during the forecast period from 2024 to 2034.

*
In 2023, the United States had the largest number of diagnosed prevalent cases of myasthenia gravis among the seven major markets (7MM), totaling approximately 133,000 cases. It is projected that these figures will increase during the forecast period from 2024 to 2034.

*
In 2023, myasthenia gravis affected 48% of males and 52% of females across the seven major markets (7MM). In the United States, there were approximately 66,000 cases among males and around 67,000 cases among females in 2023. These gender-specific incidences are projected to increase during the forecast period from 2024 to 2034.

*
Emerging treatments for myasthenia gravis like Nipocalimab, Batoclimab, Descartes-08, ENSPRYNG (satralizumab), and others hold promise to substantially impact the market size of myasthenia gravis in a positive direction.

*
Key Myasthenia Gravis Companies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others

*
Key Myasthenia Gravis Therapies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others

*
The Myasthenia Gravis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myasthenia Gravis pipeline products will significantly revolutionize the Myasthenia Gravis market dynamics.

Myasthenia Gravis Overview

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by weakness and fatigue of voluntary muscles. It occurs when the body's immune system mistakenly attacks and damages the communication between nerve cells and muscles, specifically at the neuromuscular junction.

Get a Free sample for the Myasthenia Gravis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/myasthenia-gravis-market [https://www.delveinsight.com/report-store/myasthenia-gravis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myasthenia Gravis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myasthenia Gravis Epidemiology Segmentation:

The Myasthenia Gravis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Myasthenia Gravis

*
Prevalent Cases of Myasthenia Gravis by severity

*
Gender-specific Prevalence of Myasthenia Gravis

*
Diagnosed Cases of Episodic and Chronic Myasthenia Gravis

Download the report to understand which factors are driving Myasthenia Gravis epidemiology trends @ Myasthenia Gravis Epidemiology Forecast [https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myasthenia Gravis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myasthenia Gravis market or expected to get launched during the study period. The analysis covers Myasthenia Gravis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myasthenia Gravis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myasthenia Gravis Therapies and Key Companies

*
Tolebrutinib: Sanofi

*
Descartes-08: Cartesian Therapeutics

*
Mezagitamab (TAK-079): Takeda

*
DAS-001: DAS Therapeutics, Inc.

*
Rozanolixizumab: UCB Biopharma

*
Zilucoplan: UCB Biopharma

*
Subcutaneous Efgartigimod: Argenx-Halozyme Therapeutics

*
Uplizna (Inebilizumab): Horizon Therapeutics

*
Enspryng (Satralizumab): Hoffmann-La Roche

*
Nipocalimab: Janssen Research & Development, LLC

*
Batoclimab: Immunovant Sciences GmbH

Discover more about therapies set to grab major Myasthenia Gravis market share @ Myasthenia Gravis Treatment Landscape [https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myasthenia Gravis Market Strengths

*
The growing prevalence of myasthenia gravis (MG) and the geriatric population offers a stable market demand for treatments and therapies.

*
Myasthenia gravis treatments may qualify for orphan drug status, offering regulatory incentives, such as extended market exclusivity and tax benefits.

Myasthenia Gravis Market Opportunities

*
Potential for developing new, more effective therapies, such as gene therapy or targeted biologics, could address unmet medical needs.

*
Improved diagnostic techniques using clear biomarkers and an increase in awareness will likely lead to a diagnosis of more patients, expanding the market.

Scope of the Myasthenia Gravis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM Countries

*
Key Myasthenia Gravis Companies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others

*
Key Myasthenia Gravis Therapies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others

*
Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies

*
Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Myasthenia Gravis Unmet Needs, KOL's views, Analyst's views, Myasthenia Gravis Market Access and Reimbursement

To know more about Myasthenia Gravis companies working in the treatment market, visit @ Myasthenia Gravis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Myasthenia Gravis Market Report Introduction

2. Executive Summary for Myasthenia Gravis

3. SWOT analysis of Myasthenia Gravis

4. Myasthenia Gravis Patient Share (%) Overview at a Glance

5. Myasthenia Gravis Market Overview at a Glance

6. Myasthenia Gravis Disease Background and Overview

7. Myasthenia Gravis Epidemiology and Patient Population

8. Country-Specific Patient Population of Myasthenia Gravis

9. Myasthenia Gravis Current Treatment and Medical Practices

10. Myasthenia Gravis Unmet Needs

11. Myasthenia Gravis Emerging Therapies

12. Myasthenia Gravis Market Outlook

13. Country-Wise Myasthenia Gravis Market Analysis (2020-2034)

14. Myasthenia Gravis Market Access and Reimbursement of Therapies

15. Myasthenia Gravis Market Drivers

16. Myasthenia Gravis Market Barriers

17. Myasthenia Gravis Appendix

18. Myasthenia Gravis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myasthenia-gravis-market-to-expand-significantly-by-2034-states-delveinsight-report-sanofi-cartesian-therapeutics-takeda-ucb-biopharma-hoffmannla-roche-janssen-research-development-llc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.